Citius Pharmaceuticals issues shareholder letter
Highlights of shareholder letter include:
- Successfully uplisted to Nasdaq stock exchange where the company will gain access to broader investor audience.
- Received positive response from the FDA for phase 3 trial amendments of Mino-Lok, their proprietary product that address a potential $750 million sector.
- Secured funding of more than $26.8 million, including a recent raise of $6.8 million, with significant insider participation.
- Finalized the addition of South America to The Company's worldwide license for Mino-Lok.
- Completed Phase 2a studies for Hydro-Lido, which could become the first FDA-approved product to address the estimated $500 million U.S. hemorrhoid marketplace.
10 months later
